Sign in Subscribe
Universities and colleges

Improved Dose Gradient in Prostate Cancer Treatment using CyberKnife and IMRT

Strategic Insights

— 1 min read

Researchers from the University of California have published a study on the dose gradient near the target-normal structure interface for nonisocentric CyberKnife (CK) and isocentric intensity-modulated body radiotherapy (IMRT) in prostate cancer treatment. The study aimed to compare the treatment planning quality between CK and IMRT for hypofractionated prostate body radiotherapy. The results show that CK plans demonstrate better conformity and lower dose inhomogeneity compared to IMRT plans.

Key Takeaways:

  • The study found that nonisocentric CK plans showed significantly better conformity than isocentric IMRT plans, with an average conformity index of 1.18 ± 0.08 for CK and 1.44 ± 0.11 for IMRT.
  • The average homogeneity index for CK plans was 1.45 ± 0.12, compared to 1.28 ± 0.06 for IMRT plans.
  • The percentage of dose falloff was calculated in three directions, with the lowest value recorded in the anterior direction for both CK and IMRT plans.
  • Nonisocentric CK was found to be as capable of producing equivalent fast dose falloff as high-number fixed-field IMRT delivery.
  • The study's findings suggest that CK may be a viable option for prostate cancer treatment, offering improved dose gradient characteristics compared to traditional IMRT.

Statistics:

  • Conformity index (CK): 1.18 ± 0.08
  • Conformity index (IMRT): 1.44 ± 0.11
  • Homogeneity index (CK): 1.45 ± 0.12
  • Homogeneity index (IMRT): 1.28 ± 0.06
  • Percentage of dose falloff (anterior direction, CK): 2.9% ± 0.8%/mm
  • Percentage of dose falloff (anterior direction, IMRT): 3.1% ± 1.0%/mm
  • Percentage of dose falloff (posterior direction, CK): 3.8% ± 1.6%/mm
  • Percentage of dose falloff (posterior direction, IMRT): 3.2% ± 1.9%/mm

Sources:

  • S. Hossain et al. (2010). "Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer." International Journal of Radiation Oncology, Biology, Physics, 78(1), 58-63.
  • University of California, Department of Radiation Oncology, San Francisco, CA 94143-1708 USA.

Read more